- call +1-201-465-4211
- email sales@mrinsights.biz
Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.
Scope of the Report:
This report focuses on the Pulmonary Hypertension Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Pulmonary Hypertension Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Abbott Laboratories
Boehringer Ingelheim GmbH
AstraZeneca plc
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd.
Vectura Group plc
Pfizer Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists
Phosphodiesterase-5 Inhibitors
Soluble Guanylate Cyclase Stimulators
Market Segment by Applications, can be divided into
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
There are 15 Chapters to deeply display the global Pulmonary Hypertension Drug market.
Chapter 1, to describe Pulmonary Hypertension Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Pulmonary Hypertension Drug, with sales, revenue, and price of Pulmonary Hypertension Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Pulmonary Hypertension Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Pulmonary Hypertension Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Pulmonary Hypertension Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Pulmonary Hypertension Drug Introduction
1.2 Market Analysis by Type
1.2.1 Prostacyclin and Prostacyclin Analogs
1.2.2 Endothelin Receptor Antagonists
1.2.3 Phosphodiesterase-5 Inhibitors
1.2.4 Soluble Guanylate Cyclase Stimulators
1.3 Market Analysis by Applications
1.3.1 Early-stage Drug Candidates (Phase I & Phase II)
1.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline plc
2.1.1 Business Overview
2.1.2 Pulmonary Hypertension Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis AG
2.2.1 Business Overview
2.2.2 Pulmonary Hypertension Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis AG Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck & Co., Inc.
2.3.1 Business Overview
2.3.2 Pulmonary Hypertension Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck & Co., Inc. Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Abbott Laboratories
2.4.1 Business Overview
2.4.2 Pulmonary Hypertension Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Abbott Laboratories Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Boehringer Ingelheim GmbH
2.5.1 Business Overview
2.5.2 Pulmonary Hypertension Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 AstraZeneca plc
2.6.1 Business Overview
2.6.2 Pulmonary Hypertension Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 AstraZeneca plc Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 F. Hoffmann-La Roche AG
2.7.1 Business Overview
2.7.2 Pulmonary Hypertension Drug Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Teva Pharmaceutical Industries Ltd.
2.8.1 Business Overview
2.8.2 Pulmonary Hypertension Drug Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Vectura Group plc
2.9.1 Business Overview
2.9.2 Pulmonary Hypertension Drug Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Pfizer Inc.
2.10.1 Business Overview
2.10.2 Pulmonary Hypertension Drug Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Pfizer Inc. Pulmonary Hypertension Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Pulmonary Hypertension Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Pulmonary Hypertension Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Pulmonary Hypertension Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Pulmonary Hypertension Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Pulmonary Hypertension Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Pulmonary Hypertension Drug Market Analysis by Regions
4.1 Global Pulmonary Hypertension Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Pulmonary Hypertension Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Pulmonary Hypertension Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
4.3 Europe Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
4.5 South America Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
5 North America Pulmonary Hypertension Drug by Countries
5.1 North America Pulmonary Hypertension Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Pulmonary Hypertension Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Pulmonary Hypertension Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
5.3 Canada Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
6 Europe Pulmonary Hypertension Drug by Countries
6.1 Europe Pulmonary Hypertension Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Pulmonary Hypertension Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Pulmonary Hypertension Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
6.3 UK Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
6.4 France Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
6.5 Russia Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
6.6 Italy Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Pulmonary Hypertension Drug by Countries
7.1 Asia-Pacific Pulmonary Hypertension Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Pulmonary Hypertension Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Pulmonary Hypertension Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
7.3 Japan Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
7.4 Korea Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
7.5 India Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
8 South America Pulmonary Hypertension Drug by Countries
8.1 South America Pulmonary Hypertension Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Pulmonary Hypertension Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Pulmonary Hypertension Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Pulmonary Hypertension Drug by Countries
9.1 Middle East and Africa Pulmonary Hypertension Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Pulmonary Hypertension Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Pulmonary Hypertension Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
9.3 UAE Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Pulmonary Hypertension Drug Sales and Growth Rate (2013-2018)
10 Global Pulmonary Hypertension Drug Market Segment by Type
10.1 Global Pulmonary Hypertension Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Pulmonary Hypertension Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Pulmonary Hypertension Drug Revenue and Market Share by Type (2013-2018)
10.2 Prostacyclin and Prostacyclin Analogs Sales Growth and Price
10.2.1 Global Prostacyclin and Prostacyclin Analogs Sales Growth (2013-2018)
10.2.2 Global Prostacyclin and Prostacyclin Analogs Price (2013-2018)
10.3 Endothelin Receptor Antagonists Sales Growth and Price
10.3.1 Global Endothelin Receptor Antagonists Sales Growth (2013-2018)
10.3.2 Global Endothelin Receptor Antagonists Price (2013-2018)
10.4 Phosphodiesterase-5 Inhibitors Sales Growth and Price
10.4.1 Global Phosphodiesterase-5 Inhibitors Sales Growth (2013-2018)
10.4.2 Global Phosphodiesterase-5 Inhibitors Price (2013-2018)
10.5 Soluble Guanylate Cyclase Stimulators Sales Growth and Price
10.5.1 Global Soluble Guanylate Cyclase Stimulators Sales Growth (2013-2018)
10.5.2 Global Soluble Guanylate Cyclase Stimulators Price (2013-2018)
11 Global Pulmonary Hypertension Drug Market Segment by Application
11.1 Global Pulmonary Hypertension Drug Sales Market Share by Application (2013-2018)
11.2 Early-stage Drug Candidates (Phase I & Phase II) Sales Growth (2013-2018)
11.3 Late-stage Drug Candidates (Phase III & Registration Phase) Sales Growth (2013-2018)
12 Pulmonary Hypertension Drug Market Forecast (2018-2023)
12.1 Global Pulmonary Hypertension Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Pulmonary Hypertension Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Pulmonary Hypertension Drug Market Forecast (2018-2023)
12.2.2 Europe Pulmonary Hypertension Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Pulmonary Hypertension Drug Market Forecast (2018-2023)
12.2.4 South America Pulmonary Hypertension Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Pulmonary Hypertension Drug Market Forecast (2018-2023)
12.3 Pulmonary Hypertension Drug Market Forecast by Type (2018-2023)
12.3.1 Global Pulmonary Hypertension Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Pulmonary Hypertension Drug Market Share Forecast by Type (2018-2023)
12.4 Pulmonary Hypertension Drug Market Forecast by Application (2018-2023)
12.4.1 Global Pulmonary Hypertension Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Pulmonary Hypertension Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Pulmonary Hypertension Drug Picture
Table Product Specifications of Pulmonary Hypertension Drug
Figure Global Sales Market Share of Pulmonary Hypertension Drug by Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
